Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children. Clarity’s platform technology allows peptides and antibodies to be radiolabeled for visualisation using PET imaging and therapy. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach by only treating those patients that are likely to respond to therapy and excluding those that won’t. This precision medicine approach is at the forefront of drug development.